UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF ~~THE SECURITIES EXCHANGE ACT OF 1934~~

~~Date~~THE ofSECURITIES ~~Report~~EXCHANGE ~~(Date~~ACT ofOF ~~earliest event reported): March 19, 2021~~1934

Date of Report (Date of earliest event reported): April 15, 2025

Vycor Medical, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware

001-34932

20-3369218

(State or Other Jurisdiction

of Incorporation)

(Commission

File No.)

(I.R.S. Employer

Identification No.)

951 Broken Sound Parkway, Suite 320, Boca Raton, FL		33487
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (561) 558-2020

Securities Registered Pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Each Exchange on which registered
Common Stock, par value $0.0001		VYCO		OTCQB

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[☐ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [☐ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [☐ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [☐ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock		VYCO		OTCQB

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Â§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Â§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

TABLE OF CONTENTS

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements with Certain Officers SIGNATURES

Item 2.02.	Results of Operations and Financial Conditions
Item 9.01	Financial Statements and Exhibits
SIGNATURES

Item 5 2.02. ~~Departure~~Results of ~~Directors~~Operations orand ~~Certain~~Financial ~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements with Certain Officers~~Conditions

OnThe ~~March~~information ~~19,~~in ~~2021~~this report and the ~~Company’s~~exhibit ~~Board~~attached ofhereto ~~Directors~~are ~~accepted~~being ~~the~~furnished ~~tendered~~pursuant ~~resignations~~to Item 2.02 of ~~Steven~~Form ~~Girgenti~~8-K and ~~Lowell~~shall ~~Rush~~not asbe deemed ~~Directors~~“filed” offor ~~the~~purposes ~~Company~~of ~~for~~Section ~~personal~~18 ~~reasons.~~of ~~The~~the ~~resignations~~Securities ~~are~~Exchange ~~effective~~Act as of ~~April 1~~1934, ~~2021.~~nor ~~The~~shall ~~Board~~they ~~expressed~~be ~~its~~deemed ~~appreciation~~incorporated by reference ~~for~~in ~~Messrs.~~any ~~Girgenti’s~~filing with the Securities and ~~Rush’s~~Exchange ~~many~~Commission ~~years~~under the Securities Act of ~~service~~1934 toor the ~~Company.~~Securities ~~There~~Act ~~were~~of no1933, ~~disagreements~~except ~~between~~as ~~the Company~~shall ~~and~~be ~~either~~expressly ofset ~~Messrs.~~forth ~~Girgenti~~by ~~and/or~~specific ~~Rush~~reference onto ~~any~~such ~~matters~~filing.

On April 15, 2025, we issued a press release regarding our financial results for the year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

Non-GAAP Measures

We make reference to non-GAAP financial information in this press release together with a reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures. Specifically, we have provided non-GAAP Cash Operating Expenses and non-GAAP Cash Operating Loss measures that exclude Depreciation and non-cash Stock Compensation.

We believe that these non-GAAP financial measures provide investors with insight into what is used by management to conduct a more meaningful and consistent comparison of our ongoing operating results and trends, compared with historical results. This presentation is also consistent with the measures management uses to measure the performance of ongoing operating results against prior periods and against our internally developed targets. There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP and the reconciliation of non-GAAP financial measures in this press release.

Item 9.01. Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit 99.1.	Vycor Medical, Inc. Press Release dated April 15, 2025.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Vycor Medical, Inc.
By:	/s/ Peter C. Zachariou
Name:	Peter C. Zachariou
Title:	Chief Executive Officer
Dated: March 22, 2021
Dated:	April 15, 2025

Filing Compare · VYCOR MEDICAL INC